Myeloproliferative neoplasms, which include polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are blood cancers in which a single mutated hematopoietic stem cell expands and crowds out its healthy competitors. The result is excessive production of red blood cells, platelets, or other myeloid lineages, along with a heightened risk of thrombosis and, in some patients, transformation to acute leukemia. Interferon-α has been used therapeutically in these diseases since the 1980s, and modern pegylated formulations can achieve molecular remissions in a substantial fraction of patients. Yet the drug’s mechanism of action at the level of individual stem cells and their clonal descendants has remained incompletely understood.

To dissect this mechanism, the researchers employed single-cell multiomics, a suite of techniques that measures gene expression and other molecular features in thousands to millions of individual cells simultaneously. By profiling hematopoietic stem and progenitor cells isolated from patients with myeloproliferative neoplasms, they were able to trace how mutant and wild-type clones respond to interferon-α exposure at single-cell resolution. This approach is critical because bulk measurements average across heterogeneous cell populations and can mask the clonal dynamics that ultimately determine treatment response.

The study’s central discovery is that interferon-α perturbs clonal competition by reshaping blood development along two complementary axes. The first axis involves lymphoid differentiation. Rather than simply poisoning the malignant clones, interferon-α augments the capacity of hematopoietic stem and progenitor cells to generate lymphoid lineages, the family of blood cells that includes lymphocytes and other immune cells. Because myeloproliferative neoplasm clones are typically skewed toward myeloid output, promoting lymphoid differentiation has the net effect of normalizing the distorted lineage balance that defines these diseases. Blood counts fall toward normal not because cells are killed indiscriminately, but because the developmental trajectory of the stem cell pool is redirected.

The second axis involves inflammatory myeloid differentiation. Interferon-α modulates the clonal dynamics of the disease by driving myeloid cells through inflammatory differentiation states. Inflammatory myelopoiesis, the emergency production of myeloid cells in response to infection or tissue damage, is normally a transient process. In the context of myeloproliferative neoplasms, interferon-α appears to co-opt these inflammatory programs in ways that alter the fitness and behavior of competing clones. Cells that pass through interferon-stimulated inflammatory states may lose their proliferative advantage, slowing the expansion of the mutant clone relative to residual normal hematopoiesis.

Together, these two mechanisms reframe how interferon therapy should be understood. Type 1 interferons are best known as the body’s first line of antiviral defense, released by infected cells to warn neighbors and place them in an antiviral state. But interferon signaling also acts as a regulator of hematopoiesis, the lifelong process by which hematopoietic stem cells replenish all blood lineages. The new data indicate that this immunological signaling molecule functions as an ecological force within the bone marrow, changing which clones thrive and which decline. Clonal competition, the Darwinian struggle among stem cells carrying different genetic and epigenetic states, is thus not only governed by cell-intrinsic mutations but also by inflammatory cues from the environment.

This perspective carries significant implications for personalized medicine in myeloproliferative neoplasms. Treatment response to interferon-α varies widely among patients, and the reasons have been obscure. If the drug’s efficacy depends on reshaping clonal architecture through lymphoid and inflammatory differentiation programs, then the baseline developmental and inflammatory state of a patient’s hematopoietic system may predict response. Single-cell profiling could, in principle, identify which patients harbor clones susceptible to interferon-mediated redirection and which carry clones that resist these pressures, guiding therapeutic selection before months of treatment.

The findings also resonate with a broader theme in modern hematology: the recognition that inflammation shapes clonal hematopoiesis throughout life. Age-related clonal hematopoiesis, in which mutant clones expand in otherwise healthy individuals, is accelerated by inflammatory conditions, and inflammatory cytokines can favor the expansion of clones carrying mutations in genes such as TET2 and DNMT3A. The new study extends this logic to therapeutic interferon signaling, showing that a clinically administered cytokine can deliberately manipulate the same clonal competition that inflammation naturally influences. In effect, interferon-α therapy converts an ecological principle into a treatment strategy.

Technically, the power of the single-cell multiomics approach lies in its ability to resolve fates that would otherwise be invisible. By capturing transcriptomic profiles of individual hematopoietic stem and progenitor cells, researchers can identify rare subpopulations, quantify lineage priming, and detect interferon-stimulated gene expression programs at the level of single cells. When combined with clonal tracking, this reveals whether lymphoid-skewed or inflammatory cells derive from mutant or wild-type ancestors, and how interferon exposure shifts the contributions of each. Such resolution is essential for distinguishing a true change in stem cell behavior from a passive consequence of cell death or selective survival.

For patients, the study provides reassurance that interferon-α’s benefits rest on comprehensible biology rather than blunt cytotoxicity. Normalizing blood counts by restoring balanced lineage output, rather than by depleting the marrow, suggests a therapeutic modality that works with the regenerative machinery of hematopoiesis instead of against it. It also raises the possibility of combination strategies designed to amplify the lymphoid-promoting effects of interferon or to potentiate the inflammatory states that disadvantage malignant clones, potentially lowering drug doses and reducing the side effects that have historically limited interferon therapy.

Looking forward, the work opens several avenues of investigation. Researchers will want to determine which downstream interferon signaling components mediate the lymphoid differentiation boost, how inflammatory myeloid states translate into altered clonal fitness, and whether similar mechanisms operate in other hematologic malignancies treated with interferons. Longitudinal single-cell studies tracking individual patients before, during, and after therapy could reveal the kinetics of clonal reshaping and identify the molecular signatures of durable molecular remission. More broadly, the study positions type 1 interferon not merely as an antiviral cytokine but as a master regulator of developmental competition within human tissues, a concept likely to influence how clinicians and scientists think about inflammation, stem cells, and cancer therapy in the years ahead.

Subject of Research: How interferon-α reshapes human blood development and clonal competition in myeloproliferative neoplasms

Article Title: Type 1 interferon perturbates clonal competition by reshaping human blood development

Article References: Lama, C., Isakov, D., Rosenberg, S., Quijada-Álamo, M., Saurty-Seerunghen, M. S., Moein, S., Nozais, M., Abera, T.-A., Sakaguchi, O., Totwani, M., Freed, G., Zaydon, L., Poon, C.-L., Parghi, N., Kubas-Meyer, A., Xie, A. X., Omar, M., Choi, D., Castillo-Tokumori, F., … Nam, A. S. (2026). Type 1 interferon perturbates clonal competition by reshaping human blood development. Nature Genetics. https://doi.org/10.1038/s41588-026-02751-3

Image Credits: AI Generated

DOI: 10.1038/s41588-026-02751-3

Keywords: type 1 interferon, interferon-alpha, clonal competition, hematopoietic stem cells, myeloproliferative neoplasms, single-cell multiomics, lymphoid differentiation, inflammatory myeloid differentiation, blood counts, hematopoiesis, clonal hematopoiesis, Nature Genetics

Systemic lupus erythematosus is a complex autoimmune disease in which the immune system turns against the body’s own tissues, attacking the skin, joints, kidneys, blood cells, and other organs with chronic inflammation. Genetics plays a substantial role in determining who develops lupus, and many of the genetic regions associated with disease risk have been catalogued for years through large-scale association studies. A major challenge, however, has been moving from statistical association to biological mechanism. Knowing that a stretch of DNA correlates with disease risk says little about what the inherited variant actually does inside immune cells, or why it increases susceptibility not just to lupus but frequently to several autoimmune conditions at once. The new study addresses that gap directly by dissecting what one of the most prevalent lupus-risk haplotypes does to the function of IRF7, a gene whose protein product orchestrates the production of type I interferons, the chemical alarm signals that mobilize antiviral defense throughout the body.

IRF7 helps cells respond to viral infection by activating the production of type I interferons, most notably interferon-alpha, or IFN-α. These signaling molecules are essential components of innate immunity, spreading rapidly from infected cells to their neighbors and instructing them to enter a defensive state that makes viral replication far more difficult. But type I interferon signaling has long been strongly implicated in lupus as well. Many patients with lupus carry a chronically elevated interferon activity in their blood, a phenomenon so consistent that researchers refer to it as the ‘interferon signature,’ and therapies designed to block this pathway have already been approved for treating the disease. The Cincinnati Children’s team reasoned that the connection between these two observations, effective antiviral defense on one side and pathological interferon activity on the other, might run through the genetic variation within IRF7 itself.

That reasoning proved correct. The researchers found that the lupus risk haplotype increases IRF7-dependent induction of IFN-α. In practical terms, individuals carrying this common genetic configuration mount a stronger interferon response under the conditions studied, meaning their antiviral alarm system can ring louder and faster when a viral threat is detected. That heightened responsiveness can be a genuine asset in fighting infection. Yet the very same biology can also promote excessive or inappropriate immune activation, tipping the balance of the immune system toward the self-directed inflammation that defines lupus. The study thereby exposes what the authors describe as an important biological tradeoff, in which a single inherited configuration of the immune system confers both an advantage and a vulnerability depending on context.

The evolutionary implications are striking. A more vigorous antiviral immune response may have been enormously beneficial throughout human history, particularly during eras when infectious diseases represented one of the greatest threats to survival. Populations in which individuals responded more forcefully to viral invasion may have withstood epidemics that devastated others. But an immune system that is especially sensitive to viral signals also carries a greater inherent tendency to cross the line from protective immunity into autoimmunity. The new findings therefore suggest that at least some lupus risk variants should not be thought of as ‘defective’ versions of immune genes at all. Instead, they represent versions of the immune system that simply perform differently, offering an advantage in one environment while increasing disease susceptibility in another. This reframing helps explain why such variants remained common: natural selection may have favored them precisely because of the very biology that now contributes to autoimmune disease.

Sam Virolainen, PhD, first author of the study and a graduate of the Immunology Graduate Program at Cincinnati Children’s, said the findings help explain why a genetic variant linked to lupus remained so common and how, biologically, it affects the immune system more broadly. Reflecting on the training that shaped the work, Virolainen noted an appreciation gained during doctoral research in the Kottyan and Weirauch laboratories that many genetic risk factors can contribute to multiple diseases, especially when the immune system is involved. That multiscale perspective, spanning molecular regulation, cellular signaling, and population genetics, is evident throughout the study’s design and interpretation, and it underscores how a variant’s effect can ripple across very different levels of biological organization.

The work also feeds into a larger and still-unresolved question: how inherited genetic risk interacts with viral infection in the development of autoimmunity. For years, researchers have recognized a strong relationship between Epstein-Barr virus, or EBV, and lupus. Nearly everyone is exposed to EBV at some point in their lives, yet only a small fraction of those exposed ever develop lupus. Genetics may help explain why the consequences of the same viral exposure differ so dramatically from one person to the next. The research team’s previous work examined how viral proteins, including those produced by EBV, interact with the human genome at regions associated with autoimmune disease. The new IRF7 study approaches the gene-virus relationship from the opposite direction. Rather than asking how a virus interacts with genetically susceptible cells, the team asked how inherited genetic variation changes the antiviral response itself, and the answer places both processes on converging molecular roads.

‘Together, these studies support a model in which genetic susceptibility and viral exposure are not independent risk factors. They can converge on the same regulatory pathways,’ said Kottyan. In this model, a person’s inherited genome shapes how strongly their immune system reacts to infection, while viral infection in turn activates molecular pathways that are already tuned by that genetic makeup. In some individuals, the interaction of the two may explain how an ordinary antiviral immune response develops into chronic autoimmune inflammation. The lupus-risk IRF7 haplotype amplifies the interferon arm of this convergence, but the principle likely extends to other immune genes and other autoimmune conditions, offering a framework in which genetics and environment are treated as intertwined rather than separate contributors to disease.

The study does not immediately change how lupus is diagnosed or treated, and carrying this genetic haplotype does not mean that someone will develop the disease. Lupus arises from the combined effects of many genetic variants together with environmental exposures and other biological factors, and no single inherited element is decisive on its own. However, the research demonstrates how scientists can move beyond simply identifying genetic risk factors to understanding, at a mechanistic level, how those variants alter immune function. Studies of this kind help build a foundation for future research into what drives disease and why its course differs from person to person. ‘I am hopeful that our work will increase our understanding of not just lupus biology but other diseases with similar genetic and immunologic complexities,’ said Virolainen. Many disease-associated variants have already been identified, but their biological effects remain unclear. By clarifying the molecular pathways involved, the Cincinnati Children’s team and their collaborators, who spanned institutions across 13 U.S. states and territories and six countries, may ultimately help guide therapies that target disease more precisely while preserving the normal antiviral function that those same variants evolved to protect.

Subject of Research: Genetic and immunological mechanisms linking a common IRF7 haplotype to enhanced antiviral defense and increased lupus risk

Article Title: When Antiviral Defense and Autoimmunity Collide: New Insights into Lupus Genetics

Article References: When Antiviral Defense and Autoimmunity Collide: New Insights into Lupus Genetics. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: lupus, systemic lupus erythematosus, IRF7, interferon-alpha, autoimmunity, antiviral immunity, genetic haplotype, Epstein-Barr virus, transcription factor, immune genetics, Cincinnati Children's, interferon signature